Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer.
Foldi J, Silber A, Reisenbichler E, Singh K, Fischbach N, Persico J, Adelson K, Katoch A, Horowitz N, Lannin D, Chagpar A, Park T, Marczyk M, Frederick C, Burrello T, Ibrahim E, Qing T, Bai Y, Blenman K, Rimm DL, Pusztai L.
Foldi J, et al. Among authors: marczyk m.
NPJ Breast Cancer. 2021 Feb 8;7(1):9. doi: 10.1038/s41523-021-00219-7.
NPJ Breast Cancer. 2021.
PMID: 33558513
Free PMC article.